WO1998031386A1 - Procede de stabilisation de peptides et compositions medicinales lyophilisees comprenant des peptides obtenus par ce procede - Google Patents
Procede de stabilisation de peptides et compositions medicinales lyophilisees comprenant des peptides obtenus par ce procede Download PDFInfo
- Publication number
- WO1998031386A1 WO1998031386A1 PCT/JP1998/000178 JP9800178W WO9831386A1 WO 1998031386 A1 WO1998031386 A1 WO 1998031386A1 JP 9800178 W JP9800178 W JP 9800178W WO 9831386 A1 WO9831386 A1 WO 9831386A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hirudin
- peptide
- organic acid
- freeze
- gly
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/855—Proteins from animals other than mammals or birds
Definitions
- the present invention has an -Asp-Gly- or -Asn-Gly- sequence in its amino acid sequence, wherein the -Asp-Gly- or -Asn-Gly- sequence has a dehydration reaction or a deamidation reaction.
- the present invention relates to a method for stabilizing a peptide which suppresses the change of a peptide which is converted to a succinimide form by the isomerization reaction and further changes to a -transferred form by the isomerization reaction, in particular, distulfat hirudin or hirudin mutant.
- the present invention also relates to a peptide-containing lyophilized pharmaceutical composition in which the change is suppressed by using the stabilization method.
- Hirudin is an anticoagulant factor secreted from the salivary gland of the medicinal leech (Hirudo medicinalis) and has an antithrombin effect. Hirudin, together with its variants, has been developed as an anticoagulant drug.
- hirudin or hirudin mutants contain the -Asp-Gly- or -Asn-Gly- sequence, which changes to a succinimide at that portion of the sequence over time, and furthermore, yS- Turns into metastases. For this reason, even if it is sufficiently purified on the production line, this succinimide or 3-transformation occurs during storage, and the purity is reduced.
- the succinimide or ⁇ -transferant itself also has antithrombin activity (see Japanese Patent Application Laid-Open No. 5-310788), and the purity reduction caused by this change is generally a problem. The power that must not be. When viewed as a pharmaceutical product, it was not desirable.
- the present invention has been made to solve the above problems. That is, the object of the present invention is to suppress the change of the -Asp-Gly- or -Asn-Gly- sequence to a succinimido form or a 3-transferred form, thereby producing a peptide containing this type of sequence.
- An object of the present invention is to provide a method for stabilizing a peptide that increases stability, and a freeze-dried pharmaceutical composition containing hirudin having excellent stability using the method for stabilizing a peptide. According to the present invention, the following general formula (1)
- disulfatohirudin or hirudin mutant is used as the peptide of the present invention.
- the present invention relates to a pharmaceutical composition prepared using the above-described method for stabilizing a peptide, specifically, 5 to 1 relative to 1 mole of distulfatohirudin or a hirudin mutant as a composition ratio.
- This is a lyophilized pharmaceutical composition containing hirudin to which 00 mol of an organic acid has been added.
- the present invention provides a freeze-drying 1 to 500 moles of sucrose and, if necessary, 100 to 100 moles of mannitol, in addition to the above organic acid, are added to the disulphatohirudin or mutant of hirudin It was done.
- FIG. 1 shows a liquid chromatographic chromatogram of a freeze-dried sample stored in a 40 incubator in Experimental Example 6 for 3 months.
- the numbers in the figure are prescription numbers.
- the method of the present invention comprises an amino acid sequence consisting of -Asp-Gly- or -Asn-Gly- in a peptide, and the sequence is represented by the above general formula (1) or (2) over time. It can suppress the change to the expressed succinimide or 3-transferred form. Therefore, the present invention can be applied to any peptide having an Asp-Gly or Asn-Gly sequence.
- disulfatohirudin HV-1 Japanese Patent Application Laid-Open No. 60-136) No. 597
- H V-2 Japanese Patent Application Laid-Open No. 60-136) No. 597
- hirudin mutant HV 1 C 3 represented by SEQ ID NO: 1 (see Japanese Patent Application Laid-Open No. 4-177379). Particularly, it is particularly suitable for hirudin mutant HV 1 C 3 (SEQ ID NO: 1 in the Sequence Listing) such as human growth hormone or lysozyme. Further, the amino acid sequence is further modified based on the above-mentioned disulfato hirudin HV-1 or hirudin mutant HV 1 C3, and the sequence of -Asp-Gly- or -Asn-Gly- Are holding various hirudin mutants, for example, European Patent Publication
- rHV-1-9 SEQ ID NO: 2
- rHV-1-10 SEQ ID NO: 3
- rHV-1-14 SEQ ID NO: 4
- rHV-1-15 SEQ ID NO: 5
- rHV-1-16 SEQ ID NO: 6
- HV- described in International Publication WO09 / 15610 The same applies to 17 (SEQ ID NO: 7).
- the above-mentioned peptide is dissolved in water so as to have a final concentration of 0.1 to 500 mM, and then, the organic acid and, if necessary, hydroxylation. Adjust the pH to 5 to 6.5 by adding an aqueous solution of sodium hydroxide or the like.
- Examples of the organic acid in this case include various carboxylic acids that are acceptable as excipients, for example, monobasic acid, acetic acid, lactic acid, dibasic acid or tribasic acid, tartaric acid, citric acid, lithium acid.
- Cornic acid can be used (particularly, dibasic acid or tribasic acid, tartaric acid, citric acid, etc., or monobasic acid, acetic acid, etc. are effective in improving peptide stability). More generally, those having a structure in which a hydroxyl group is substituted on the carbon at the ⁇ -position of the carboxylic acid, that is, a chain having a partial structure of C—CH (OH) —COOH.
- Carboxylic acids, especially dibasic acids or tribasic acids are more preferred, and lyophilization of this peptide solution in a state where the pH is less than 5 or more than 6.5 results in stability. Significantly impaired.
- the organic concentration of 5-100 mM relative to these hirudin ImM is required. It is preferable to add an acid and, if necessary, an appropriate amount of an aqueous solution of Arikari. By freeze-drying this, a hirudin-containing freeze-dried pharmaceutical composition can be obtained. In this case, the lyophilized product in which only the organic acid is added becomes a fluffy and fluffy state, and the operation during production and administration becomes complicated.
- the peptide solution prepared as described above is preferably isotonic, and is freeze-dried by a general-purpose method. This lyophilized product can be used immediately for administration by redissolving.
- the content of the components to be added to the pharmaceutical composition is determined by the peptide solution used for preparing the freeze-dried pharmaceutical composition, that is, the solution to be freeze-dried. Expressed by the concentration (final concentration). Also, pH means pH in the solution to be freeze-dried.
- Hirudin mutant having the amino acid sequence shown in SEQ ID NO: 1 HV 1 C3 6 mg / ml (0.86 mM), glycine 6.7 mg / ml (89 mM), mannitol 33.5 mg / ml It was dissolved in purified water to a concentration of ml (184 mM). This solution was divided into six portions, and adjusted to the pH shown in Table 1 using 3 OmM of tartaric acid, phosphoric acid, and Tris buffer to obtain a peptide solution. The pH-adjusted solution and the unadjusted solution were filtered through a 0.22 / zm membrane filter, and the filtrate was placed in a 6-ml vial at a volume of 1 ml. A total of 350 tubes were freeze-dried.
- the peak area percentage of hirudin mutant HV1C3 was determined by liquid chromatography under the conditions shown in Table 2, and the hirudin in the original lyophilized sample before storage in the incubator was determined. It was determined as a percentage remaining for the mutant HV 1 C3, and the results are shown in Table 1.
- Purified hirudin mutant HV1C3 to a concentration of 6 mg / ml (0.86 mM), purified sucrose to a concentration of 1.6 mg / ml (4.7 mM), and mannitol to a concentration of 10 mg / ml (55 mM) Dissolved in water. This solution was divided into 5 portions, and the pH of each of the 4 portions was adjusted to 5. using 30 mM acetic acid, tartaric acid, citric acid, and phosphoric acid.
- the hirudin mutant HV1C3 was dissolved in purified water to a concentration of 6 mg / ml (0.86 mM) and purified sucrose to a concentration of 1.6 mg / ml (4.7 mM), and this solution was divided into 4 parts, of which 3 parts PH was adjusted to 5.5 peptide solution using 5 mM, 10 mM, and 30 mM of tartaric acid, respectively. Mannitol was dissolved in the unadjusted solution to a concentration of 10 mg / ml (55 mM). These solutions were filtered through a 0.22 ⁇ m membrane filter, and 1 ml of each filtrate was placed in a 6-ml vial, and 50 of each were freeze-dried, for a total of 200 tubes.
- Each of the lyophilized samples showed a stable form, and purified sucrose and mannitol were effective as excipients. These lyophilized samples, 60. Store in a C incubator and remove at 4 and 8 weeks, respectively.Add 1 ml of purified water to 1 vial, dilute 50-fold, and perform liquid chromatography under the same conditions as in Experimental Example 1. The peak area percentage of the amount of the isomer other than the hirudin mutant HV 1 C 3 was determined by the chromatography. Table 6 shows the results.
- Fig. 1 shows the chromatogram at this time.
- such a change in a peptide such as a disulfato-hirudin or a hirudin mutant, that changes over time to a succinimide or yS-transferred -Asp-Gly- or -Asn-Gly- sequence. It can be suppressed efficiently and the stability of these peptides can be increased.
- V u IOS niO ⁇ 3 ⁇ 4 ⁇ person ds v Jill J person 1 ⁇ 1 ⁇ ⁇
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU54976/98A AU721149C (en) | 1997-01-20 | 1998-01-19 | Method for stabilizing peptide and peptide-containing lyophilized pharmaceutical composition using the method |
NZ336793A NZ336793A (en) | 1997-01-20 | 1998-01-19 | Method for stabilizing peptides by adding an organic acid and then lyophilizing the peptide mixture |
CA002278199A CA2278199A1 (en) | 1997-01-20 | 1998-01-19 | Method for stabilizing peptides and freeze-dried medicinal compositions containing peptides obtained by using the method |
EP98900424A EP0998942A4 (en) | 1997-01-20 | 1998-01-19 | METHOD FOR STABILIZING PEPTIDES AND FREEZERED MEDICINAL COMPOSITIONS THEREOF |
US09/341,926 US6274553B1 (en) | 1997-01-20 | 1998-01-19 | Method for stabilizing peptides and freeze-dried medicinal compositions containing peptides obtained by using the method |
NO993533A NO993533L (no) | 1997-01-20 | 1999-07-19 | FremgangsmÕte for stabilisering av peptider, samt frysetörkede medisinske preparater som inneholder peptider erholdt ved Õ anvende fremgangsmÕten |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9/20957 | 1997-01-20 | ||
JP2095797 | 1997-01-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998031386A1 true WO1998031386A1 (fr) | 1998-07-23 |
Family
ID=12041671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/000178 WO1998031386A1 (fr) | 1997-01-20 | 1998-01-19 | Procede de stabilisation de peptides et compositions medicinales lyophilisees comprenant des peptides obtenus par ce procede |
Country Status (9)
Country | Link |
---|---|
US (1) | US6274553B1 (ja) |
EP (1) | EP0998942A4 (ja) |
KR (1) | KR20000070338A (ja) |
CA (1) | CA2278199A1 (ja) |
NO (1) | NO993533L (ja) |
NZ (1) | NZ336793A (ja) |
RU (1) | RU2180218C2 (ja) |
WO (1) | WO1998031386A1 (ja) |
ZA (1) | ZA98438B (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8114959B2 (en) | 2003-06-03 | 2012-02-14 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
US8114833B2 (en) | 2003-11-20 | 2012-02-14 | Novo Nordisk A/S | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
US8710181B2 (en) | 2004-08-31 | 2014-04-29 | Novo Nordisk A/S | Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins |
US8748376B2 (en) | 2004-11-12 | 2014-06-10 | Novo Nordisk A/S | Stable formulations of peptides |
US8846618B2 (en) | 2001-06-28 | 2014-09-30 | Novo Nordisk A/S | Stable formulation of modified GLP-1 |
US11318191B2 (en) | 2020-02-18 | 2022-05-03 | Novo Nordisk A/S | GLP-1 compositions and uses thereof |
US11752198B2 (en) | 2017-08-24 | 2023-09-12 | Novo Nordisk A/S | GLP-1 compositions and uses thereof |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2292254A3 (en) * | 2003-06-03 | 2011-12-14 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
WO2005094891A2 (en) * | 2004-03-12 | 2005-10-13 | Intercell Ag | Method for solubilising peptide mixtures |
AU2008343052A1 (en) | 2007-12-21 | 2009-07-09 | Lyotropic Therapeutics, Inc. | Stabilized formulations of peptides and proteins |
JP5406049B2 (ja) * | 2008-02-05 | 2014-02-05 | 協和発酵バイオ株式会社 | グルタチオンの保存安定性向上方法 |
US7582727B1 (en) | 2008-07-27 | 2009-09-01 | The Medicinces Company | Pharmaceutical formulations of bivalirudin and processes of making the same |
US7598343B1 (en) | 2008-07-27 | 2009-10-06 | The Medicines Company | Pharmaceutical formulations of bivalirudin and processes of making the same |
US7803762B1 (en) * | 2009-08-20 | 2010-09-28 | The Medicines Company | Ready-to-use bivalirudin compositions |
US7985733B1 (en) | 2010-01-06 | 2011-07-26 | The Medicines Company | Buffer-based method for preparing bivalirudin drug product |
US11992514B2 (en) | 2019-05-20 | 2024-05-28 | MAIA Pharmaceuticals, Inc. | Ready-to-use bivalirudin compositions |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60136597A (ja) * | 1983-11-22 | 1985-07-20 | チバ−ガイギ− アクチエンゲゼルシヤフト | デスルフアトヒルジン、その製造及びそれを含む製薬組成物 |
JPH02117694A (ja) * | 1988-07-19 | 1990-05-02 | Ciba Geigy Ag | デスルファトヒルジン変異体 |
JPH04327539A (ja) * | 1991-03-08 | 1992-11-17 | Ciba Geigy Ag | 癌転移の阻止又は予防のための方法及び製剤 |
JPH05247090A (ja) * | 1991-02-28 | 1993-09-24 | Farmitalia Carlo Erba Spa | 抗トロンビンポリペプチド |
JPH05310789A (ja) * | 1991-12-07 | 1993-11-22 | Hoechst Ag | 安定性の改善された新規な合成イソヒルジン |
JPH06256214A (ja) * | 1993-02-18 | 1994-09-13 | Ciba Geigy Ag | ヒルジンを含んで成る水性貯蔵配合物 |
JPH07267877A (ja) * | 1994-01-26 | 1995-10-17 | Ciba Geigy Ag | ヒルジン含有医薬組成物 |
JPH09227407A (ja) * | 1996-02-27 | 1997-09-02 | Behringwerke Ag | ヒルジンを含有する医薬組成物およびその製法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3019612A1 (de) | 1980-05-22 | 1981-11-26 | Boehringer Mannheim Gmbh, 6800 Mannheim | Stabilisiertes thrombinpraeparat |
US5059587A (en) * | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
US5164304A (en) | 1989-05-04 | 1992-11-17 | Sri International | Method and vectors for stabilizing hirudin and human laminin b1 expression |
AU641215B2 (en) | 1990-02-13 | 1993-09-16 | Merrell Dow Pharmaceuticals Inc. | Stabilized sulfonate, sulfate, phosphonate and phosphate derivatives of hirudin |
US5278289A (en) | 1991-11-12 | 1994-01-11 | Johnson Alan J | Antihemophilic factor stabilization |
ATE173739T1 (de) * | 1992-04-30 | 1998-12-15 | Cor Therapeutics Inc | Stabile zusammensetzung von polypeptiden |
US5747447A (en) | 1992-04-30 | 1998-05-05 | Cor Therapeutics | Stable polypeptide composition |
US5409725A (en) | 1992-06-23 | 1995-04-25 | Philip Connolly | Methods for stabilizing proteins in an acid pH environment and related compositions |
US6165981A (en) * | 1995-03-07 | 2000-12-26 | Dade Behring Inc. | Stabilizing solutions for proteins and peptides |
-
1998
- 1998-01-19 RU RU99118176/14A patent/RU2180218C2/ru active
- 1998-01-19 CA CA002278199A patent/CA2278199A1/en not_active Abandoned
- 1998-01-19 US US09/341,926 patent/US6274553B1/en not_active Expired - Fee Related
- 1998-01-19 EP EP98900424A patent/EP0998942A4/en not_active Withdrawn
- 1998-01-19 WO PCT/JP1998/000178 patent/WO1998031386A1/ja not_active Application Discontinuation
- 1998-01-19 NZ NZ336793A patent/NZ336793A/xx unknown
- 1998-01-19 KR KR1019997006569A patent/KR20000070338A/ko not_active Application Discontinuation
- 1998-01-20 ZA ZA98438A patent/ZA98438B/xx unknown
-
1999
- 1999-07-19 NO NO993533A patent/NO993533L/no unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60136597A (ja) * | 1983-11-22 | 1985-07-20 | チバ−ガイギ− アクチエンゲゼルシヤフト | デスルフアトヒルジン、その製造及びそれを含む製薬組成物 |
JPH02117694A (ja) * | 1988-07-19 | 1990-05-02 | Ciba Geigy Ag | デスルファトヒルジン変異体 |
JPH05247090A (ja) * | 1991-02-28 | 1993-09-24 | Farmitalia Carlo Erba Spa | 抗トロンビンポリペプチド |
JPH04327539A (ja) * | 1991-03-08 | 1992-11-17 | Ciba Geigy Ag | 癌転移の阻止又は予防のための方法及び製剤 |
JPH05310789A (ja) * | 1991-12-07 | 1993-11-22 | Hoechst Ag | 安定性の改善された新規な合成イソヒルジン |
JPH06256214A (ja) * | 1993-02-18 | 1994-09-13 | Ciba Geigy Ag | ヒルジンを含んで成る水性貯蔵配合物 |
JPH07267877A (ja) * | 1994-01-26 | 1995-10-17 | Ciba Geigy Ag | ヒルジン含有医薬組成物 |
JPH09227407A (ja) * | 1996-02-27 | 1997-09-02 | Behringwerke Ag | ヒルジンを含有する医薬組成物およびその製法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0998942A4 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8846618B2 (en) | 2001-06-28 | 2014-09-30 | Novo Nordisk A/S | Stable formulation of modified GLP-1 |
US8114959B2 (en) | 2003-06-03 | 2012-02-14 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
US8114833B2 (en) | 2003-11-20 | 2012-02-14 | Novo Nordisk A/S | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
US8710181B2 (en) | 2004-08-31 | 2014-04-29 | Novo Nordisk A/S | Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins |
US8748376B2 (en) | 2004-11-12 | 2014-06-10 | Novo Nordisk A/S | Stable formulations of peptides |
US11752198B2 (en) | 2017-08-24 | 2023-09-12 | Novo Nordisk A/S | GLP-1 compositions and uses thereof |
US11318191B2 (en) | 2020-02-18 | 2022-05-03 | Novo Nordisk A/S | GLP-1 compositions and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP0998942A1 (en) | 2000-05-10 |
US6274553B1 (en) | 2001-08-14 |
RU2180218C2 (ru) | 2002-03-10 |
CA2278199A1 (en) | 1998-07-23 |
EP0998942A4 (en) | 2006-08-16 |
ZA98438B (en) | 1998-07-29 |
NO993533L (no) | 1999-09-17 |
NZ336793A (en) | 2000-08-25 |
AU5497698A (en) | 1998-08-07 |
KR20000070338A (ko) | 2000-11-25 |
NO993533D0 (no) | 1999-07-19 |
AU721149B2 (en) | 2000-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998031386A1 (fr) | Procede de stabilisation de peptides et compositions medicinales lyophilisees comprenant des peptides obtenus par ce procede | |
JP5753692B2 (ja) | タンパク質製剤 | |
JP4046388B2 (ja) | 亜鉛結合が増大したインシュリン誘導体 | |
CN101809029B (zh) | 具有延长目标肽的血浆半衰期作用的肽 | |
US20180193422A1 (en) | Highly active polypeptides and methods of making and using the same | |
CA2187083C (fr) | Fragment peptidique de la proteine g du virus respiratoire syncytial, agent immunogene, composition pharmaceutique le contenant et procede de preparation | |
DE60032926T2 (de) | Verbesserung von peptid-transport durch konjugation mit gallensäuren | |
JP2001525371A (ja) | Glp−1製剤 | |
CZ123198A3 (cs) | Stabilní lyofilizovaný farmaceutický prostředek | |
JP2022095872A (ja) | ヒトインスリンまたはそのアナログのアシル化誘導体 | |
BG64272B1 (bg) | 'Ъ''АВИ, 'ЪДЪРЖА(tm)И ПРО'ИВОГЪБИ-НО 'Р...Д''ВО И А-...'А'...Н Б""...Р | |
EA016804B1 (ru) | Циклические конструкты натрийуретических пептидов | |
CN102643339A (zh) | 一种glp-1类似物、制备方法及其应用 | |
US20200384085A1 (en) | Peptides comprising non-natural amino acids and methods of making and using the same | |
JP5982562B2 (ja) | ペプチドの塩酸塩及び他のペプチドとの併用によるその免疫治療用途 | |
JP4402296B2 (ja) | 亜鉛結合性が増大された新規なインスリン同族体 | |
EA012287B1 (ru) | Фармацевтическая композиция glp-1 | |
WO1997014430A1 (en) | Use of thioethers as antioxidant for peptides and proteins and compositions containing the thioethers | |
JP5647609B2 (ja) | 経粘膜吸収性を付与したモチリン類似ペプチド化合物 | |
CN108025039B (zh) | 新颖的大环化合物 | |
JP2020519250A (ja) | 副甲状腺ホルモン融合ポリペプチド | |
US4963529A (en) | Stable growth hormone releasing factor preparation | |
WO2009107766A1 (ja) | 経鼻投与用医薬組成物 | |
CN116034159A (zh) | 新型肾上腺髓质素类似物及其制备方法和医药用途 | |
WO2023153507A1 (ja) | 腹膜障害用の医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA KR NO NZ RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 336793 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2278199 Country of ref document: CA Ref country code: CA Ref document number: 2278199 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997006569 Country of ref document: KR Ref document number: 54976/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998900424 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09341926 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998900424 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 54976/98 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997006569 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019997006569 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998900424 Country of ref document: EP |